EUDA Health Holdings Ltd. (EUDA) is asking shareholders to approve a dual-class structure, changing its authorized shares to an unlimited number of Class A ordinary shares and 2,000,000 Class B ordinary shares. The proposal would reclassify 437,824 shares held by Tan Meng Dong and affiliate 8i Capital Limited as Class B, along with 1,562,176 authorized but unissued shares. Each Class B share would carry 50 votes, compared with one vote per Class A share.
If the proposals are approved and the amended memorandum and articles are filed, Tan Meng Dong and 8i Capital would hold 437,824 Class B shares, representing approximately 14.6% of outstanding shares and approximately 89.5% of voting power. These figures exclude 14,000 Class A shares held in escrow without voting rights. Shareholders will also vote on adopting the amended governing documents and allowing adjournment to permit further proxy solicitation. The virtual meeting is scheduled for October 30, 2026; proxies must be received before 11:59 p.m. Eastern Time on October 29, 2026.
EUDA Health Holdings Ltd filed an amendment to its Amended and Restated Memorandum of Association and Articles of Association with the British Virgin Islands Registrar of Corporate Affairs on October 5, 2026. A copy of the company’s current amended and restated documents was attached.
EUDA Health Holdings Limited reported revenue of $3,467,835 for the six months ended June 30, 2026, compared with $3,057,323 in the same 2025 period. Net loss narrowed to $796,950 from $1,201,696. Property management services generated $2,255,161, and holistic wellness consumer products and services generated $1,212,674. Net cash used in operating activities was $1,206,041; cash and cash equivalents were $365,904 at June 30, 2026.
EUDA reported 16,000,000 QB Tokens at a fair value of $7,560,000 as of June 30, 2026, after obtaining control on May 19, 2026; consideration was $250,000 cash and 500,000 ordinary shares. The company also reported $3,750,000 of proceeds from issuing 625,000 ordinary shares through a direct offering. Management cited working capital of approximately $5.5 million and determined that conditions raise substantial doubt about EUDA’s ability to continue as a going concern within one year after issuance of the financial statements.
EUDA Health Holdings Limited has filed a resale prospectus covering up to 947,963 ordinary shares, including 7,306 shares issuable upon exercise of 292,250 warrants. All shares may be sold from time to time by existing shareholders; the company is not selling shares and will not receive resale proceeds.
The registered shares include 500,000 shares issued under a Simple Agreement for Future Tokens with QB Limited and shares held by affiliates. Ordinary shares outstanding were 2,994,325 as of July 31, 2026, or 3,001,631 assuming full exercise of the registered warrants.
EUDA distributes non-invasive healthcare products and property management services in Asia and is developing a digital health and rewards platform integrating QB Utility Tokens. EUDA discloses recurring losses, a going concern explanatory paragraph, and a material weakness in internal control over financial reporting, alongside extensive risks related to token integration, reliance on third parties, regulation and capital needs.
EUDA Health Holdings Limited has filed an amended Form F-3 to register the resale of up to 947,963 ordinary shares by existing shareholders. The shares comprise 500,000 shares issued under a Simple Agreement for Future Tokens with QB Limited, 440,657 shares held by affiliates, and 7,306 shares issuable upon exercise of 292,250 outstanding warrants.
EUDA will not receive any proceeds from these sales, though it will cover registration expenses. The business now centers on property management and a growing wellness distribution arm following the discontinuation of medical services. The company reports recurring losses, a going-concern explanatory paragraph, and a material weakness in internal controls, and expects to need additional capital.
The filing also details a planned digital health and rewards platform integrating QB Utility Tokens, of which EUDA purchased 16 million tokens for ecosystem use. Token issuance, supply and governance remain under QB Limited’s control, and extensive risk factors highlight operational, regulatory, liquidity and technology risks around both the core business and the token-based platform.
EUDA Health Holdings Limited describes a planned collaboration under a non-binding Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. The parties plan to combine GO POSB’s induced pluripotent stem cell platform and universal tumor organoid bank with SIIT’s Natural Killer and NK-TCR cell engineering and GMP manufacturing capabilities to explore off-the-shelf cell therapies for wellness and oncology.
The initiative targets future global distribution, subject to definitive agreements, sufficient funding, manufacturing, testing, clinical evaluation and regulatory approvals. EUDA positions this program within its strategy as a distributor of wellness and non-invasive healthcare products in Asia, aiming to address the needs of over 1.8 billion people in a region where more than 30% of the population is rapidly aging.
EUDA Health Holdings Limited entered into a tri-party Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. to collaborate on next-generation therapies derived from induced pluripotent stem cells, including NK-TCR cell therapies.
The company states this collaboration is a significant milestone that aligns with its strategy to strengthen commercialization and distribution of innovative, science-backed wellness and non-invasive healthcare products and services. EUDA focuses on Singapore, Malaysia and China and aims to serve over 1.8 billion people in a region where more than 30% of the population is rapidly aging, with an emphasis on the longevity sector.
Euda Health Holdings Limited reports that it has terminated its at-the-market equity offering program and the related At The Market Offering Agreement with Chardan Capital Markets, LLC. The program had previously allowed sales of ordinary shares with an aggregate offering price of up to $10.0 million, but this capacity had been reduced to zero and no ordinary shares were sold. All related prospectus supplements are also terminated as of the date of this supplement. The company’s ordinary shares trade on the NASDAQ Capital Market under the symbol EUDA, and the closing price was $15.30 on July 21, 2026.